

## Ovarian Cancer: Effective Practices to Benefit Patients

- In advanced ovarian cancer, genetic testing rates hover around 50%.<sup>1</sup>
- Only 49% of patients received maintenance therapy in second line or greater therapy.<sup>2</sup>
- Current rates warrant improved methods and practices to enable professionals to both identify and offer PARP-Inhibitors to appropriate patients at the right time.
  - **NCODA's Positive Quality Intervention (PQI)** on this topic provides practical guidance and is available here: [www.ncoda.org/ovarian-cancer-parp-inhibitor-eligibility](http://www.ncoda.org/ovarian-cancer-parp-inhibitor-eligibility)

**This EMR Resource provides simple step-by-step instructions to:**

 **1. Run a Report:** to search for all ovarian cancer patients

 **2. Review Chart:** to conduct a clinical assessment

 **3. Create Reminders and Track:** key treatment milestones and timing of therapy

### 1. Run a Report

To identify all ovarian cancer patients within the EMR, search by "Ovarian"

Work with your **Information Technology (IT) Department**  
to run the report


**Gain access to institution-specific software**  
that pulls data from Cerner

Examples include HealtheAnalytics, Business Objects, and  
Data Cube

If needed, **work with Cerner support directly** to run the report


2. Review Chart

From the patient list, select a patient and review each patient case to determine



3. Create Reminders and Track

For each patient, create a tracking system and reminder flag via Patient List, case management software, or Outlook Calendar



1. Randall LM, Aydin E, Louie-Gao M, Hazard S, Westin SN. A retrospective analysis of real-world tumor BRCA (tBRCA) testing trends in ovarian cancer before and after PARP inhibitor approvals. Presented at the 17<sup>th</sup> Biennial Meeting of the International Gynecologic Cancer Society; Kyoto, Japan: 2018.  
2. Garofalo D, Verma-Kurvari S, Aydin E, et al. Real world data analysis of ovarian cancer maintenance utilization among maintenance eligible patients. Presented at the American Society of Clinical Oncology Annual Congress; Chicago, IL: 2019.

